Considerations for Moderna's move to get an EUA for the COVID-19 vaccine in young kids

Video

Editorial board member Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, discusses the recently release topline data, the potential timeline, and what potential stumbling blocks could be.

Editorial board member Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, discusses the recently release topline data, the potential timeline, and what potential stumbling blocks could be.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!
Recent Videos
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Jennifer Soung, MD reacts to FDA approval of roflumilast foam 0.3%
Suzanne Hollander, MS, RD, LDN, Senior Clinical Nutrition Specialist, Boston Children's Hospital | Image credit: Boston Children's
Russell Libby, MD, FAAP
Lawrence Eichenfield, MD
Related Content
Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis

Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis

Mercedes E. Gonzalez, MD
June 27th 2025
Article

Roflumilast cream 0.05% is being studied for mild-to-moderate AD in infants aged 3 months to under 2 years in a new phase 2 trial.

FDA approves at-home belimumab autoinjector for children with lupus nephritis |© Contemporary Pediatrics

FDA approves at-home belimumab autoinjector for children with lupus nephritis

Morgan Ebert, Managing Editor
June 24th 2025
Article

The FDA has approved belimumab (Benlysta; GSK) autoinjector for children with lupus nephritis, expanding at-home treatment.

Weekly review: New PrEP for HIV, new HAE treatment, and more | Image credit: © Artur - stock.adobe.com.

Weekly review: New PrEP for HIV, new HAE treatment, and more

Joshua Fitch, Senior Editor
June 23rd 2025
Article

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

FDA extends review of ruxolitinib cream for pediatric atopic dermatitis | Image credit: Contemporary Pediatrics.

FDA extends review of ruxolitinib cream for pediatric atopic dermatitis

Morgan Ebert, Managing Editor
June 20th 2025
Article

The FDA has extended the review of ruxolitinib for atopic dermatitis in children 2 to 11 years to September 2025 to evaluate new CMC data.

FDA approves lenacapavir as PrEP for HIV in adults, adolescents weighing at least 35 kg | Image Credit: Contemporary Pediatrics

FDA approves twice-yearly lenacapavir as PrEP for HIV in adolescents, adults

Joshua Fitch, Senior Editor
June 18th 2025
Article

Lenacapavir is the first twice-yearly option available in the US for those who need or want PrEP, according to Gilead Sciences.

Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins | Image Credit: © 125154153 - stock.adobe.com.

Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins

Joshua Fitch, Senior Editor
June 18th 2025
Article

Currently, omaveloxolone (Skyclarys) is approved to treat adults and adolescents aged 16 years and older impacted by FA.

© 2025 MJH Life Sciences

All rights reserved.